# NCTN Breast Cancer Trials Portfolio (Open as of 10/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

## Neoadjuvant

**S2212 (SCARLET)**
TNBC
T2-4/N0/M0, or T1-3/N1-2/M0

**S2206**
HR+/HER2-
Stage II or III

## Post-Neoadjuvant

**A012103 (OptimICE-PCR)**
TNBC
Early-Stage, pCR post pre-op chemo + pembrolizumab

**A012303 (ShortStop-HER2)**
HER2+
Early-Stage, pCR post pre-op chemo + HER2 blockade

## Adjuvant

**NRG-BR009 (OFSET)**
HR+/HER2-
pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients

**EA1242 (RxFINE-Low)**
HR+/HER2-
pT0-3/N0-3/M0, Oncotype Recurrence Score ≤ 25, Postmenopausal patients

## Metastatic

**S2511**
HER2+
De Novo, Stage IV oligometastatic (≤ 5 lesions)

**EAY191 (ComboMATCH)**

## Legend by Subtype Status

Green = TNBC

Orange = HER2+ (Any HR status)

Purple = HR+ and HER2-

Pink = Cross-disease trial

# NCTN Breast Cancer Trials (Open as of 10/15/2026)

| Protocol Number | Phase | Protocol Title |
|---|---|---|
| **A012103** | III | OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy |
| **A012303** | III | ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade |
| **EA1242** | III | A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS</=25 (RxFINE-Low) |
| **NRG-BR009** | III | A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET) |
| **S2206** | III | Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer |
| **S2212** | III | Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study |
| **S2511** | III | Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer with Response to Initial Chemotherapy |
| **EAY191** | Other | Molecular Analysis for Combination Therapy Choice (ComboMATCH) |

**This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find-a-study/**